RxDoctor Payments Data

Phuong le

Optometrist · Westminster, CANPI 1356532600

Payments from drug & device makers

$1,578in general payments, 2019–2025

Across 34 payments — averaging $46.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$614
  • Glaukos Corporation$241
  • Sun Pharmaceutical Industries Inc.$158
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$123
  • AstraZeneca$122
  • Visioneering Technologies, Inc.$100
  • plus $222 from 7 others

What the payments were for

  • Food & beverage$1,49895%
  • Education$181%
  • Entertainment$634%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,578 in reported general payments places this provider in the 70th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$99,162
Medicare patients
359
Services billed
1,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine198$163,263
Cyclosporine210$88,862
LumiganBimatoprost71$16,925
Latanoprost775$9,798
EysuvisLoteprednol Etabonate16$7,874
RocklatanNetarsudil Mesylat/Latanoprost15$7,784
XiidraLifitegrast11$7,590
AzoptBrinzolamide12$4,225
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$4,074
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat168$3,517
Travoprost25$3,245
Brimonidine Tartrate16$1,803
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha68$814
Timolol Maleate43$655
Cromolyn Sodium16$395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$24$180,187269 claims
Bausch & Lomb Americas Inc.Xiidra$18$7,59011 claims
AlconAzopt$50$4,22512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,778 optometrist providers in California.

Other optometrist in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →